Personensuche
Personensuche
Es wurde 1 Person gefunden.
Funktionen
-
, Klinik für Hämatologie
Aktuelle Veranstaltungen
Keine aktuellen Veranstaltungen.
Vergangene Veranstaltungen (max. 10)
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia : Results From the Randomized, Placebo-Controlled Phase 2 DELTA TrialIn: American Journal of Hematology, Jg. 100, 2025, Nr. 12, S. 2436 – 2441DOI (Open Access)
-
Salvage autologous transplant in relapsed multiple myeloma : long-term follow-up of the phase 3 GMMG ReLApsE trialIn: Blood, Jg. 145, 2025, Nr. 16, S. 1780 – 1787DOI (Open Access)
-
Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML : The Randomized DaunoDouble Trial by the Study Alliance LeukemiaIn: Journal of Clinical Oncology (JCO), Jg. 43, 2025, Nr. 1, S. 65 – 74
-
Decitabine in Older Patients with AML : Quality of Life Results of the EORTC-GIMEMA-GMDS-SG Randomized Phase III TrialIn: Blood, Jg. 144, 2024, Nr. 5, S. 541 – 551DOI (Open Access)
-
Gemtuzumab ozogamicin plus midostaurin in combination with standard ‘7 + 3’ induction therapy in newly diagnosed AML : Results from the SAL-MODULE phase I studyIn: British Journal of Haematology, Jg. 204, 2024, Nr. 6, S. 2254 – 2258DOI (Open Access)
-
Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapyIn: European Journal of Nuclear Medicine and Molecular Imaging, Jg. 51, 2024, Nr. 5, S. 1361 – 1370DOI (Open Access)
-
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia : An open-label, randomised, controlled, phase 3 trialIn: The Lancet Haematology, Jg. 10, 2023, Nr. 11, S. e879 – e889
-
Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell TherapyIn: HemaSphere: Open Access Journal of the European Hematology Association, Jg. 7, 2023, Nr. 1, S. E817DOI (Open Access)
-
UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcomeIn: Blood Cancer Journal, Jg. 13, 2023, Nr. 1, 88DOI (Open Access)
-
CEBPA mutations in 4708 patients with acute myeloid leukemia : differential impact of bZIP and TAD mutations on outcomeIn: Blood, Jg. 139, 2022, Nr. 1, S. 87 – 103DOI (Open Access)
-
Differential impact of IDH1/2 mutational subclasses on outcome in adult AML : Results from a large multicenter studyIn: Blood Advances, Jg. 6, 2022, Nr. 5, S. 1394 – 1405DOI (Open Access)
-
A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapyIn: Leukemia, Jg. 35, 2021, Nr. 3, S. 701 – 711DOI (Open Access)
-
Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide : An international collaborative studyIn: Haematologica / The Hematology Journal, Jg. 106, 2021, Nr. 12, S. 3100 – 3106DOI (Open Access)
-
Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemiaIn: Blood Advances, Jg. 5, 2021, Nr. 17, S. 3279 – 3289DOI (Open Access)
-
Loss-of-function mutations of bcor are an independent marker of adverse outcomes in intensively treated patients with acute myeloid leukemiaIn: Cancers, Jg. 13, 2021, Nr. 9, S. 2095DOI (Open Access)
-
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma : the randomized GMMG phase III trial ReLApsEIn: Leukemia, Jg. 35, 2021, S. 1134 – 1144
-
Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia : Long-term follow-up of the randomized controlled SORAML trialIn: Leukemia, Jg. 35, 2021, Nr. 9, S. 2517 – 2525DOI (Open Access)
-
Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?In: Blood, Jg. 136, 2020, Nr. 7, S. 823 – 830DOI (Open Access)
-
EZH2 mutations and impact on clinical outcome : An analysis in 1,604 patients with newly diagnosed acute myeloid leukemiaIn: Haematologica / The Hematology Journal, Jg. 105, 2020, Nr. 5, S. E228 – E231DOI (Open Access)
-
Etoposide combined with FLAG salvage therapy is effective in multiple relapsed / refractory acute myeloid leukemiaIn: Acta Haematologica, Jg. 143, 2020, Nr. 5, S. 438 – 445DOI (Open Access)
-
FLAG salvage therapy combined with idarubicin in relapsed/refractory acute myeloid leukemiaIn: Leukemia and Lymphoma, Jg. 60, 2019, Nr. 4, S. 1014 – 1022
-
Plerixafor in non-Hodgkin’s lymphoma patients : a German analysis of time, effort and costsIn: Bone Marrow Transplantation, Jg. 54, 2019, Nr. 1, S. 123 – 129DOI (Open Access)
-
Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia : results of a phase Ib trialIn: British Journal of Haematology, Jg. 185, 2019, Nr. 3, S. 595 – 598DOI, Online Volltext (Open Access)
-
Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid LeukemiaIn: Blood, Jg. 134, 2019, Nr. Suppl. 1, S. 13DOI (Open Access)
-
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2) : An open-label, multicentre, phase 2 trialIn: The Lancet Oncology, Jg. 19, 2018, Nr. 12, S. 1668 – 1679
-
Plerixafor in poor mobilizers with non-Hodgkin’s lymphoma : a multi-center time-motion analysisIn: Bone Marrow Transplantation, Jg. 53, 2018, Nr. 3, S. 246 – 254DOI (Open Access)
-
Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients : A subgroup analysis from the phase III trial ReLApsEIn: European Journal of Haematology, Jg. 99, 2017, Nr. 1, S. 42 – 50
-
Retrospective analysis of FLAG-idarubicin and FLAG-etoposide as salvage therapies in relapsed/refractory acute myeloid leukemiaIn: Oncology Research and Treatment, Jg. 40, 2017, Nr. Suppl. 3, Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Stuttgart, 29. September-3. Oktober 2017: Abstracts, S. 43
-
Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia : The AML-AZA trial of the Study Alliance LeukemiaIn: Leukemia, Jg. 30, 2016, Nr. 3, S. 555 – 561
-
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma : Final Results From a Phase I StudyIn: Journal of Clinical Oncology (JCO), Jg. 34, 2016, Nr. 10, S. 1104 – 1111
-
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE : a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantatioIn: BMC Cancer, Jg. 16, 2016, S. 290DOI (Open Access)
-
A phase IB/II study to evaluate the safety and efficacy of vismodegib in relapsed/refractory acute myelogenous leukemiaIn: Haematologica / The Hematology Journal, Jg. 100, 2015, Nr. Suppl. 1, S. 380 – 380(Open Access)
-
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML) : a multicentre, phase 2, randomised controlled trialIn: The Lancet Oncology, Jg. 16, 2015, Nr. 16, S. 1691 – 1699
-
Effiency and toxicity of cyclophasphamide based stem cell mobilization relapsed multiple myeloma patients : Observations from the ongoing phase III trial relapseIn: Haematologica / The Hematology Journal, Jg. 100, 2015, Nr. Suppl. 1, S. 258 – 259(Open Access)
-
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blastsIn: Blood, Jg. 126, 2015, Nr. 3, S. 291 – 299
-
Updated results from the soraml trial comparing sorafenib versus placebo in addition to standard therapy in younger patients with newly diagnosted acute myeloid leukemiaIn: Haematologica / The Hematology Journal, Jg. 100, 2015, Nr. Suppl. 1, S. 318 – 318(Open Access)
-
Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia : results from a randomized, placebo-controlled trialIn: Journal of Clinical Oncology (JCO), Jg. 31, 2013, Nr. 25, S. 3110 – 3118
-
Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot studyIn: PLoS ONE, Jg. 7, 2012, Nr. 12, S. e52695DOI (Open Access)
-
Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin : a randomized phase II trial in elderly patientsIn: Annals of Oncology, Jg. 23, 2012, Nr. 4, S. 990 – 996
-
NK alloreactivity is reduced by GCSF but enhanced by plerixaforIn: Bone Marrow Transplantation, Jg. 47, 2012, Nr. Suppl. 1, S. 236
-
NK alloreactivity is reduced by GCSF but enhanced by plerixaforIn: Tissue Antigens, Jg. 79, 2012, Nr. 6, S. 459 – 460
-
Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure : safety and efficacy data in a series of 21 patients from Europe and the USAIn: Bone Marrow Transplantation, Jg. 47, 2012, Nr. 1, S. 18 – 23
-
Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II studyIn: Clinical Lymphoma, Myeloma & Leukemia, Jg. 11, 2011, Nr. 5, S. 433 – 438
-
CD34-Subpopulations and Clonogenic Progenitors in Mobilized Peripheral Blood Cells from Patients with Acute Myeloid LeukemiaIn: TumorDiagnostik & Therapie, Jg. 31, 2010, S. 269 – 275
-
Plerixafor for PBSC mobilization in myeloma patients with advanced renal failure : safety and efficacy data in a series of 12 patients from the US or European Compassionate Use Programmes, and from the US post-licensingIn: Bone Marrow Transplantation, Jg. 45, 2010, Nr. Suppl. 2, S. S323 – S324
-
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.In: Science, Jg. 5891, 2008, Nr. 321, S. 974 – 977
-
Health-related quality of life results of the EORTC-GIMEMAGMDS-SG randomized phase III trial AML21 : ten-day decitabine versus standard induction chemotherapy (IC) followed by allografting in older fit patients with acute myeloid leukemia
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment. Basel: Karger, Jg. 46, 2023, Nr. Supplement 5: DGHO Abstracts, S. 46 – 47DOI (Open Access) -
Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma : Long Term Follow up Results of the Randomized GMMG Phase III Multicenter Trial Relapse
65th Annual Meeting of the American-Society-of-Hematology (ASH); DEC 09-12, 2023; San Diego, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 142, 2023, Nr. Supplement 1, S. 782 – 784DOI (Open Access) -
Single vs double induction with "7+3" containing 60 vs 90 mg daunorubicin for newly diagnosed acute myeloid leukemia : results from the randomized controlled SAL-DaunoDouble trial
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment. Basel: Karger, Jg. 46, 2023, Nr. Supplement 5: DGHO Abstracts, S. 27DOI (Open Access) -
UBTF Tandem Duplications are Rare but Recurrent Alterations in Adult AML and Associated with Younger Age, Myelodysplasia and Inferior Outcome
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment. Basel: Karger, Jg. 46, 2023, Nr. Supplement 5: DGHO Abstracts, S. 28DOI (Open Access) -
10-Day Decitabine Versus Intensive Chemotherapy followed by Transplantation in Fit AML Patients Aged ≥60 Years : Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SG
64th Annual Meeting and Exposition of the American Society of Hematology ; December 10 - 13, 2022, New Orleans, LA, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 140, 2022, Nr. Supplement 1, S. 1281 – 1283DOI (Open Access) -
10-Tage Decitabin vs. Standard-Induktion, mit nachfolgender allogener Stammzelltransplantation (HSZT) bei AML-Patienten ≥ 60 Jahre : eine randomisierte Phase III Intergroup-Studie der EORTC Leukemia Group, GIMEMA, CELG und GMDS-SG
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,In: Oncology Research and Treatment. Basel: Karger, Jg. 45, 2022, Nr. Supplement 2, S. 264DOI (Open Access) -
Metabolic Tumor Volume for Outcome Prediction in Patients with Large B-Cell Lymphoma Undergoing Chimeric Antigen Receptor T-Cell Treatment
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 49, 2022, Nr. Supplement 1, S. S211DOI (Open Access) -
Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML : Results from the Randomized Controlled SAL Dauno-Double Trial
64th Annual Meeting and Exposition of the American Society of Hematology ; December 10 - 13, 2022, New Orleans, LA, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 140, 2022, Nr. Supplement 1, S. 523 – 525DOI, Online Volltext (Open Access) -
Azacitidine for Pre-Emptive Treatment of Measurable-Residual Disease in MDS/AML Patients at High Risk of Hematological Relapse : Results of the Second Cohort of the RELAZA2 Trial
61st ASH Annual Meeting and Exposition, 07.-10.12.2019, Orlando, FL,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 134, 2019, Nr. Supplement_1, S. 644DOI (Open Access) -
Impact of cytogenetics at relapse on prognosis and benefit from salvage autologous stem cell transplantation in the GMMG phase III trial ReLApsE
17th International Myeloma Workshop ; September 12-15, 2019, Boston, MA, USA,In: Clinical Lymphoma, Myeloma & Leukemia. New York: Elsevier, Jg. 19, 2019, Nr. 10, Suppl., S. e286 – e287 -
Antithymocyte Globulin (ATG), CSA and eltrombopag followed by autologous stem cell transplantation in a patient with Very Severe Aplastic Anemia (vSAA) and life-threatening pneumonia
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 28. September - 2. Oktober 2018, Wien,In: Oncology Research and Treatment. Basel: Karger, Jg. 41, 2018, Nr. Suppl. 4, S. 105DOI (Open Access) -
Cardiac toxicity of two anthracycline doses in AML induction : Short term results from the randomized SAL-DaunoDouble trial
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 28. September - 2. Oktober 2018, Wien,In: Oncology Research and Treatment. Basel: Karger, Jg. 41, 2018, Nr. Suppl. 4, S. 8DOI (Open Access) -
Clinical Characteristics and Outcome in IDH1/2 Mutant AML Patients : Analysis of 3898 Newly Diagnosed Patients with Acute Myeloid Leukemia
60th ASH Annual Meeting; December 1-4, 2018; San Diego, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 132, 2018, Nr. Supplement 1, S. 1461 – 1461DOI (Open Access) -
EZH2 Mutations and Impact on Clinical Outcome Analyzed in 1604 Patients with Acute Myeloid Leukemia
60th ASH Annual Meeting; December 1-4, 2018; San Diego, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 132, 2018, Nr. Supplement 1, S. 1528 – 1528DOI (Open Access) -
Randomized comparison of 90 mg versus 60 mg daunorubicin in 7+3 standard induction for newly diagnosed acute myeloid leukemia : Results from the SAL-DaunoDouble trial
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 28. September - 2. Oktober 2018, Wien,In: Oncology Research and Treatment. Basel: Karger, Jg. 41, 2018, Nr. Suppl. 4, S. 6 – 8DOI (Open Access) -
Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma : Results of the Randomized GMMG Phase III Multicenter Trial Relapse
60th ASH Annual Meeting; December 1-4, 2018; San Diego, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 132, 2018, Nr. Supplement 1 60th ASH Annual Meeting Abstracts, S. 253 – 253DOI (Open Access) -
Subgroup Analyses of the Randomized GMMG Phase III Multicenter Trial Relapse Suggest Survival Benefit of Salvage Autologous Transplant Primarily in Low Risk Multiple Myeloma
60th ASH Annual Meeting; December 1-4, 2018; San Diego, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 132, 2018, Nr. Supplement 1, S. 254 – 254DOI (Open Access) -
The addition of sorafenib to standard AML treatment results in a substantial reduction in relapse risk and improved survival : Updated results from long-term follow-up of the randomized-controlled SORAML trial
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 28. September - 2. Oktober 2018, Wien,In: Oncology Research and Treatment. Basel: Karger, Jg. 41, 2018, Nr. Suppl. 4, S. 9DOI (Open Access) -
Blinatumomab (CD3/CD19 Bite (R) Antibody) results in a high response rate in patients with relapsed non-hodgkin lymphoma (NHL) including mantle cell lymphoma (MCL) and diffuse large B cell lymphoma (DLBCL)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Basel, 30.09.–04.10. 2011,In: Onkologie. Basel: Karger, Jg. 34, 2011, Nr. Suppl. 6, S. 190 – 191 -
Blinatumomab Monotherapy Shows Efficacy in Patients with Relapsed Diffuse Large B Cell LymphomaIn: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 118, 2011, Nr. 21, S. 711 – 712
-
Cardiac chloroma in a patient with relapsed acute myeloid leukemia
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Basel, 30.09.–04.10. 2011,In: Onkologie. Basel: Karger, Jg. 34, 2011, Nr. Suppl. 6, S. 85 -
Acquired factor X deficiency in a patient with amyloid light chain amyloidosis
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Berlin, 1.–5. Oktober 2010,In: Onkologie. Basel: Karger, Jg. 33, 2010, Nr. Suppl. 6, S. 247 – 248 -
CD3/CD19 Bispecific Bite (R) Antibody Blinatumomab Treatment of Non-Hodgkin Lymphoma (NHL) Patients : 60 mu G/M-2/D by Continuous infusion is tolerable and results in durable response
15th Congress of the European Hematology Association, Spain, Barcelona, June 10–13, 2010,In: Haematologica, the hematology journal. Pavia; Messina; Rom: Ferrata Storti Foundation, Jg. 95, 2010, Nr. Suppl. 2, S. 230 -
CD3/CD19 bispecific BiTE (R) Antibody Blinatumomab Treatment of Non-Hodgkin Lymphoma (NHL) Patients : 60 mu g/m(2)and day by Continuous Infusion is Tolerable and Results in Durable Responses
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Berlin, 1.–5. Oktober 2010,In: Onkologie. Basel: Karger, Jg. 33, 2010, Nr. Suppl. 6, S. 157 -
Induction Therapy by Ara-C Plus Daunorubicin Versus Ara-C plus Gemtuzumab Ozogamicin : Interim Analysis of a Randomized Phase II Trial of the SAL In Elderly Patients with Acute Myeloid LeukemiaIn: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 116, 2010, Nr. 21, S. 152
-
Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups
64th Annual Meeting and Exposition of the American Society of Hematology ; December 10 - 13, 2022, New Orleans,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 140, 2022, Nr. Supplement 1: 64th Annual Meeting, S. 3338 – 3340DOI (Open Access) -
Tandem Duplications of the UBTF gene in Adult AML : A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome
64th Annual Meeting and Exposition of the American Society of Hematology ; December 10 - 13, 2022, New Orleans, LA, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 140, 2022, Nr. Supplement 1, S. 6262 – 6264DOI (Open Access)